Saturday 17 October 2026
Export ICCC’s income statement to Excel — free account
ImmuCell Corporation
ICCC Healthcare Biotechnology
ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024. In the quarter to June 2026, revenue grew 11.5%, EPS grew 233.3%, free cash flow grew 54.9% and total debt fell 15.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.75
0.19
+1.80%
Follow ICCC
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.18 |
Piotroski F-Score |
7 | 7 | 1 | 1 | 7 | 5 | 7 | 2 | 2 | 2 |
Altman Z-Score |
2.80 | 1.75 | 1.04 | 2.30 | 3.77 | 2.57 | 2.68 | 2.39 | 2.95 | 4.20 |
P/S ratio |
2.01 | 1.59 | 2.22 | 2.70 | 3.16 | 2.80 | 2.56 | 3.52 | 3.92 | 2.63 |
P/FCF ratio |
44.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
2.93 | 1.92 | 0.71 | 3.00 | 4.67 | 3.55 | 4.56 | 2.42 | 3.40 | 7.82 |
Beneish M-Score |
(3.10) | (2.23) | (1.58) | (2.61) | (2.20) | (0.67) | (2.13) | (3.31) | (2.31) | (2.14) |
P/Operating CF |
115.05 | (13,568.09) | (53.58) | (38.67) | 103.31 | 274.58 | (753.60) | (279.67) | 123.76 | (67.59) |
P/B ratio |
2.05 | 1.53 | 1.55 | 1.65 | 1.86 | 1.52 | 1.21 | 1.78 | 1.73 | 1.28 |
Price to Tangible BV |
2.06 | 1.53 | 1.56 | 1.66 | 1.87 | 1.53 | 1.22 | 1.80 | 1.75 | 1.29 |
EV/Sales |
2.20 | 1.84 | 2.85 | 2.94 | 3.10 | 2.90 | 2.53 | 4.18 | 4.42 | 1.84 |
EV/EBITDA |
13.72 | 44.82 | 0.00 | 278.42 | 21.89 | 41.57 | 26.13 | 504.64 | 69.66 | 10.36 |
EV/Operating CF |
24.56 | 136.47 | (10.64) | (35.38) | 62.55 | 33.80 | 148.89 | (122.98) | 39.19 | (78.87) |
EV/FCF |
48.22 | (472.81) | (7.58) | (9.92) | (36.41) | (16.40) | (49.11) | (21.33) | (2.79) | (4.64) |
Quick Ratio |
1.82 | 1.71 | 0.75 | 2.46 | 5.08 | 4.41 | 4.17 | 1.35 | 2.49 | 5.64 |
Current Ratio |
4.26 | 3.41 | 2.73 | 4.56 | 6.42 | 5.50 | 5.29 | 2.50 | 3.64 | 6.97 |
Net Debt/EBITDA |
1.19 | 6.22 | (3.65) | 22.61 | (0.38) | 1.45 | (0.26) | 79.61 | 7.79 | (4.50) |
Debt/Assets |
21.39% | 23.37% | 27.32% | 22.81% | 20.55% | 23.54% | 21.77% | 29.84% | 26.11% | 12.20% |
Debt/Equity |
0.34 | 0.38 | 0.48 | 0.34 | 0.28 | 0.34 | 0.29 | 0.45 | 0.38 | 0.15 |
Asset Turnover |
0.63 | 0.60 | 0.39 | 0.42 | 0.45 | 0.39 | 0.38 | 0.33 | 0.35 | 0.49 |
Operating CF/Net income |
(2.38) | (0.17) | 0.81 | 0.62 | (12.19) | (1.29) | (0.18) | 0.16 | (6.99) | (0.44) |
Capex/Depreciation |
(0.44) | (0.17) | (0.69) | (1.59) | (1.05) | (1.64) | (0.41) | (1.16) | (19.59) | (4.43) |
| (3.81%) | (8.21%) | (20.86%) | (7.92%) | (0.26%) | (3.57%) | (5.11%) | (10.24%) | (0.78%) | 3.35% | |
| (2.37%) | (4.85%) | (13.03%) | (5.58%) | (0.18%) | (2.59%) | (3.63%) | (6.93%) | (0.57%) | 2.59% | |
ROIC |
3.19% | (2.99%) | (9.98%) | (4.13%) | 0.51% | (2.89%) | (2.08%) | (3.12%) | (0.53%) | 4.59% |
Return on Tangible Assets |
(3.06%) | (5.99%) | (16.57%) | (6.34%) | (0.19%) | (2.78%) | (3.60%) | (7.77%) | (0.53%) | 2.30% |
Average Days of Receivables |
45.14 | 51.95 | 45.66 | 34.57 | 51.10 | 42.75 | 43.55 | 30.97 | 47.03 | 37.95 |
Research and Development Expense of Revenue |
11.00% | 14.72% | 25.15% | 24.20% | 21.66% | 28.38% | 26.87% | 32.01% | 19.62% | 13.04% |
Selling, General and Administrative Expense of Revenue |
24.43% | 21.45% | 29.89% | 29.37% | 21.98% | 25.35% | 29.19% | 34.81% | 32.76% | 34.43% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
1.07% | 1.23% | 2.11% | 1.43% | 0.75% | 1.65% | 2.28% | 3.13% | 1.92% | 0.71% |
Graham Net Nets |
0.03 | (0.06) | (0.19) | (0.01) | 0.07 | 0.00 | 0.10 | (0.12) | (0.08) | 0.37 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.80 |
Earnings Yield |
(1.71%) | (5.63%) | (15.00%) | (5.00%) | (0.13%) | (2.35%) | (3.69%) | (6.10%) | (0.48%) | 2.32% |
Free Cash Flow Yield |
2.27% | (0.25%) | (16.94%) | (10.98%) | (2.70%) | (6.32%) | (2.02%) | (5.57%) | (40.41%) | (15.02%) |
Revenue per Share |
3.06 | 3.24 | 2.26 | 2.40 | 2.53 | 2.13 | 2.01 | 2.00 | 2.11 | 2.26 |
Operating CF per Share |
0.27 | 0.04 | (0.60) | (0.20) | 0.13 | 0.18 | 0.03 | (0.07) | 0.24 | (0.05) |
Capex per Share |
(0.13) | (0.06) | (0.24) | (0.51) | (0.34) | (0.56) | (0.14) | (0.32) | (3.58) | (0.84) |
Free Cash Flow per Share |
0.14 | (0.01) | (0.85) | (0.71) | (0.22) | (0.38) | (0.10) | (0.39) | (3.34) | (0.89) |
Cash per Share |
0.42 | 0.46 | 0.13 | 0.75 | 1.34 | 1.10 | 1.29 | 0.46 | 0.77 | 2.51 |
Shareholders Equity per Share |
3.00 | 3.37 | 3.23 | 3.92 | 4.29 | 3.92 | 4.25 | 3.96 | 4.77 | 4.67 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.00 | 3.37 | 3.23 | 3.92 | 4.29 | 3.92 | 4.25 | 3.96 | 4.77 | 4.67 |
Free Cash Flow |
1.26 | (0.10) | (6.56) | (5.51) | (1.64) | (2.71) | (0.71) | (2.15) | (16.54) | (3.78) |
Working Capital |
12.97 | 10.63 | 7.27 | 10.92 | 13.73 | 9.95 | 10.69 | 3.86 | 5.44 | 12.29 |
Capital Expenditures |
(1.21) | (0.46) | (1.89) | (3.96) | (2.59) | (4.03) | (0.94) | (1.78) | (17.71) | (3.56) |
Net Current Asset Value |
1.47 | (2.54) | (7.35) | (0.49) | 4.38 | 0.07 | 3.49 | (4.57) | (3.20) | 9.37 |
EV/EBIT |
36.87 | 0.00 | 0.00 | 0.00 | 231.90 | 0.00 | 0.00 | 0.00 | 0.00 | 19.69 |
Capex to Sales |
0.04 | 0.02 | 0.11 | 0.21 | 0.13 | 0.26 | 0.07 | 0.16 | 1.70 | 0.37 |
Price to Operating Income |
33.66 | 0.00 | 0.00 | 0.00 | 235.96 | 0.00 | 0.00 | 0.00 | 0.00 | 28.24 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.11 | 0.10 | 0.09 | 0.09 | 0.09 | 0.09 | 0.06 | 0.03 | 0.08 |
Cash ROIC |
3.16% | (0.25%) | (17.30%) | (11.87%) | (3.16%) | (5.93%) | (1.53%) | (6.33%) | (45.50%) | (11.32%) |
Accounts Receivable Turnover |
7.69 | 8.90 | 8.86 | 8.34 | 8.57 | 8.94 | 10.68 | 9.65 | 8.93 | 11.16 |
Accounts Payable Turnover |
6.80 | 8.05 | 6.59 | 6.04 | 7.14 | 6.60 | 5.72 | 3.94 | 2.88 | 3.23 |
Inventory Turnover |
1.98 | 2.49 | 1.96 | 2.39 | 4.09 | 3.68 | 2.88 | 2.64 | 2.49 | 2.75 |
Average Days of Payables |
51.43 | 48.84 | 57.00 | 66.88 | 55.66 | 58.12 | 63.80 | 76.92 | 120.74 | 167.46 |
Days of Inventory on Hand |
208.82 | 139.94 | 209.62 | 201.85 | 106.53 | 90.07 | 131.63 | 146.93 | 143.61 | 188.28 |
Average Receivables |
3.60 | 2.98 | 1.97 | 2.23 | 2.25 | 1.72 | 1.28 | 1.14 | 1.17 | 0.86 |
Average Payables |
2.38 | 2.30 | 2.06 | 1.81 | 1.48 | 1.29 | 1.22 | 1.47 | 1.81 | 1.28 |
Average Inventory |
8.19 | 7.46 | 6.93 | 4.56 | 2.59 | 2.31 | 2.43 | 2.19 | 2.09 | 1.50 |
Average Assets |
43.82 | 44.45 | 44.33 | 44.66 | 42.41 | 39.52 | 35.71 | 33.51 | 29.50 | 19.62 |
Average Common Equity |
27.29 | 26.26 | 27.69 | 31.48 | 30.42 | 28.63 | 25.37 | 22.67 | 21.66 | 15.17 |
Columns are period end dates